Nature News: 'Migraine drug is first to tackle debilitating early symptoms' [Paywall]
"Scientists have shown that a drug approved to treat migraine headaches can also alleviate debilitating non-headache symptoms, such as fatigue, brain fog and blinding light sensitivity, that occur as the...
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial
Peter J. Goadsby, Jessica Ailani, David W. Dodick, Amaal J. Starling, Chengcheng Liu, Yingyi Liu, Sung Yun Yu, Jonathan H. Smith, Elimor Brand-Schieber & Joel M...
Thanks yeah, missed it the first time. So I don't think the decrease in HHV6 is very meaningful here without a long COVID control group. Their patient group might just select for people who had a temporary flare-up of the virus and at the follow-up they were back to normal - regression to the...
Hmm, yeah maybe. They didn't make it clear enough in the full text if that is the case.
Edit: Ah actually, it seems they do say they confirm the patients were positive to be included:
With the synapse-related findings, it might be worth revisiting this other GWAS that found a nervous system related gene:
Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci (Hajdarevic et al, 2022, Brain, Behavior, and...
Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up
Ulrich Moser
[Line breaks added]
Abstract
Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and...
Well the replication set was only composed of the Cornell cohort. But maybe it's something to consider with regard to some of the specific genes picked out using the two cohorts that made up the discovery set.
Course of neuropsychological health in post-COVID patients differs 6 and 12 months after inpatient rehabilitation
Katrin Müller, Iris Poppele, Marcel Ottiger, Rainer-Christian Weber, Michael Stegbauer, Torsten Schlesinger
Background
Rehabilitation is an effective and feasible approach for...
Impact of long COVID on the health-related quality of life of Japanese patients: A prospective nationwide cohort study
Kazuma Yagi, Masahiro Kondo, Hideki Terai, Takanori Asakura, Ryusei Kimura, Ryo Takemura, Hiromu Tanaka, Keiko Ohgino, Katsunori Masaki, Ho Namkoong, Shotaro Chubachi, Jun...
Symptom Burden and Post-COVID-19 Syndrome 24 Months Following SARS-CoV-2 Infection: Longitudinal Population-Based Study
Raphael S. Peter, Lisamaria Eble, Alexandra Nieters, Stefan O. Brockmann, Siri Göpel, Uta Merle, Jürgen M. Steinacker, Hans-Georg Kräusslich, Dietrich Rothenbacher, Winfried...
Long-COVID in children and their parents: A prospective cohort study
Hiroyuki Iijima, Takanori Funaki, Mitsuru Kubota
[Line breaks added]
Background
Long-COVID is a significant global health concern, regardless of age. However, few reports have longitudinally evaluated the characteristics...
The rising cost of Long COVID and ME/CFS in Germany
Link to summary webpage
Link to full report
______________________________
This post has been copied and discussion moved to a new thread:The rising cost of Long COVID and ME/CFS in Germany, 2025, ME Research Foundation
This post has been copied and discussion moved from
Germany: ME/CFS Research Foundation
The rising cost of Long COVID and ME/CFS in Germany
Link to summary webpage
Link to full report
No one study anywhere in science stands alone. Even if it's not as robust as a study with 20,000 people, it still adds to the weight of the evidence, and seeing replications between DecodeME and this study would strengthen the findings. Even a giant study will likely have some meaningless...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.